RT Journal Article
SR Electronic
T1 An integrated clinical and genetic model for predicting risk of severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.30.20204453
DO 10.1101/2020.09.30.20204453
A1 Gillian S. Dite
A1 Nicholas M. Murphy
A1 Richard Allman
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.30.20204453.abstract
AB Background Age and gender are often the only considerations in determining risk of severe COVID-19. There is an urgent need for accurate prediction of the risk of severe COVID-19 for use in workplaces and healthcare settings, and for individual risk management.Methods Clinical risk factors and a panel of 64 single-nucleotide polymorphisms were identified from published data. We used logistic regression to develop a model for severe COVID-19 in 1,582 UK Biobank participants aged 50 years and over who tested positive for the SARS-CoV-2 virus: 1,018 with severe disease and 564 without severe disease. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC).Results A model incorporating the SNP score and clinical risk factors (AUC=0.786) had 111% better discrimination of disease severity than a model with just age and gender (AUC=0.635). The effects of age and gender are attenuated by the other risk factors, suggesting that it is those risk factors – not age and gender – that confer risk of severe disease. In the whole UK Biobank, most are at low or only slightly elevated risk, but one- third are at two-fold or more increased risk.Conclusions We have developed a model that enables accurate prediction of severe COVID-19. Continuing to rely on age and gender alone to determine risk of severe COVID-19 will unnecessarily classify healthy older people as being at high risk and will fail to accurately quantify the increased risk for younger people with comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank has Research Tissue Bank approval (REC #11/NW/0382) that covers analysis of data by approved researchers. We conducted this research using the UK Biobank resource under Application Number 47401.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe are not permitted to share our UK Biobank data with other researchers. Instead, researchers can apply directly to the UK Biobank to use the data. We are happy to share the analysis programs for this paper.